SnapShot: Tumor angiogenesis.
Cell. 2012;149(6):1408-1408.e1 - PMID: 22682256 - DOI: 10.1016/j.cell.2012.05.025
Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis.
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Cold Spring Harb Perspect Med. 2012;2(3):a006486 - PMID: 22393532 - PMCID: PMC3282493 - DOI: 10.1101/cshperspect.a006486
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Cancer Discov. 2011;1(4):352-65 - PMID: 22145099 - PMCID: PMC3229203 - DOI: 10.1158/2159-8290.CD-11-0106
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Cancer Res. 2012;72(2):402-7 - PMID: 22127927 - PMCID: PMC3261301 - DOI: 10.1158/0008-5472.CAN-11-2464
Fluid forces control endothelial sprouting.
Proc Natl Acad Sci U S A. 2011;108(37):15342-7 - PMID: 21876168 - PMCID: PMC3174629 - DOI: 10.1073/pnas.1105316108
Cell-surface sensors for real-time probing of cellular environments.
Nat Nanotechnol. 2011;6(8):524-31 - PMID: 21765401 - PMCID: PMC3163485 - DOI: 10.1038/nnano.2011.101
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.
Nat Rev Drug Discov. 2011;10(6):417-27 - PMID: 21629292 - DOI: 10.1038/nrd3455
Molecular mechanisms and clinical applications of angiogenesis.
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
Cancer Res. 2011;71(11):3745-52 - PMID: 21507932 - PMCID: PMC3107375 - DOI: 10.1158/0008-5472.CAN-10-2991
T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
J Cereb Blood Flow Metab. 2011;31(10):2054-64 - PMID: 21505476 - PMCID: PMC3208147 - DOI: 10.1038/jcbfm.2011.39
Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
J Clin Oncol. 2011;29(1):1-4 - PMID: 21115866 - DOI: 10.1200/JCO.2010.32.2701
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.
Int J Radiat Oncol Biol Phys. 2011;81(4):1081-90 - PMID: 20932656 - PMCID: PMC3021107 - DOI: 10.1016/j.ijrobp.2010.07.024
Delivering nanomedicine to solid tumors.
Nat Rev Clin Oncol. 2010;7(11):653-64 - PMID: 20838415 - PMCID: PMC3065247 - DOI: 10.1038/nrclinonc.2010.139
Notch leads lymphatics and links them to blood vessels.
Arterioscler Thromb Vasc Biol. 2010;30(9):1682-3 - PMID: 20720193 - PMCID: PMC2945915 - DOI: 10.1161/ATVBAHA.110.210633
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119
Lymphotoxin-alpha contributes to lymphangiogenesis.
Blood. 2010;116(12):2173-82 - PMID: 20566898 - PMCID: PMC2951858 - DOI: 10.1182/blood-2009-12-256065
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis.
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
J Clin Oncol. 2010;28(2):183-5 - PMID: 19949009 - DOI: 10.1200/JCO.2009.24.8021
Determinants of leukocyte margination in rectangular microchannels.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo.
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast.
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
A new target for tumor therapy.
N Engl J Med. 2009;360(25):2669-71 - PMID: 19535806 - PMCID: PMC4792114 - DOI: 10.1056/NEJMcibr0902054
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.
Anti-vascular endothelial growth factor therapy for malignant glioma.
Curr Neurol Neurosci Rep. 2009;9(3):254-62 - PMID: 19348715 - PMCID: PMC4790123 - DOI: 10.1007/s11910-009-0037-2
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.
Cancer Res. 2009;69(7):2801-8 - PMID: 19318557 - PMCID: PMC2670480 - DOI: 10.1158/0008-5472.CAN-08-4051
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Neuro Oncol. 2009;11(6):853-60 - PMID: 19293394 - PMCID: PMC2802405 - DOI: 10.1215/15228517-2009-010
Visualizing anti-tumor immune responses in vivo.
Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells.
Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice.
Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization.
Nat Clin Pract Cardiovasc Med. 2007;4(9):491-502 - PMID: 17712362 - DOI: 10.1038/ncpcardio0979
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175
American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Microvasc Res. 2007;74(2-3):72-84 - PMID: 17560615 - PMCID: PMC2100036 - DOI: 10.1016/j.mvr.2007.05.003
Influence of tumor cell and stroma sensitivity on tumor response to radiation.
Cancer Res. 2007;67(9):4016-21 - PMID: 17483312 - DOI: 10.1158/0008-5472.CAN-06-4498
Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?
Lancet Oncol. 2007;8(5):444-8 - PMID: 17466902 - PMCID: PMC2712886 - DOI: 10.1016/S1470-2045(07)70140-7
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
1143